3 completed, 3 terminated, 3 unknown, 2 recruiting. 8 Phase 2, 6 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Unknown 3, Completed 2, Terminated 2, Recruiting 1 |
| Phase 1 | 6 | Terminated 3, Unknown 2, Recruiting 1 |
| Phase 3 | 2 | Completed 1, Recruiting 1 |
Follow Antengene Corporation: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Selinexor in Combination With MTX+Ritu to Treat R/R CNSL Selinexor, Rituximab, Methotrexate - Central Nervous System Lymphoma | Phase 1 / Phase 2 | Recruiting | Tong Chen, MD | 30 | 2023-08-03 | 2025-09-16 |
| Selinexor in Combination With HAD or CAG Rregimens in Relapsed or Refractory Acute Myeloid Leukemia Selinexor, Homoharringtonine, Daunorubicin - Relapsed or Refractory Acute Myeloid Leukemia | Phase 3 | Recruiting | Shanxi Bethune Hospital | 50 | 2023-01-29 | 2024-10-22 |
| Selinexor in Combination With R-CHOP Followed by Selinexor Maintenance for Untreated EBV-positive DLBCL Patients Selinexor, R-CHOP Protocol - EBV-Positive Diffuse Large B-Cell Lymphoma, Nos | Phase 1 / Phase 2 | Unknown | Sun Yat-sen University | 54 | 2022-11-01 | 2023-12-14 |
| Selinexor Plus R-CHOP in High-risk GCB-subtype Diffuse Large B-Cell Lymphoma Selinexor, Rituximab, Cyclophosphamide - DLBCL Germinal Center B-Cell Type | Phase 2 | Unknown | Li Zhiming | 50 | 2022-07-26 | 2024-06-17 |
| Selinexor Plus VRd in High Risk Newly Diagnosed Multiple Myeloma Selinexor, Bortezomib, Lenalidomide - Multiple Myeloma | Phase 1 / Phase 2 | Unknown | Xia Zhongjun | 42 | 2022-07-25 | 2024-06-17 |
| A Study of ATG-010 in Combination With Lenalidomide and Rituximab (R2) in Adults With DLBCL and iNHL ATG-010, Lenalidomide, Rituximab - Diffuse Large B-cell Lymphoma, Indolent Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Terminated | Antengene Corporation | 54 | 2022-04-07 | 2025-06-09 |
| A Study of ATG-010 in Combination With ATG-008 in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma ATG-010 and ATG-008 - Relapsed/Refractory Diffuse Large B-cell Lymphoma | Phase 1 | Terminated | Antengene Corporation | 7 | 2022-03-02 | 2023-03-17 |
| A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) SVd (Selinexor+Bortezomib+dexamethasone), Vd (Bortezomib+dexamethasone) - Relapsed or Refractory Multiple Myeloma | Phase 3 | Completed | Antengene Corporation | 154 | 2021-07-12 | 2026-08-10 |
| A Study of Evaluating the Safety and Efficacy of ATG-010 Combined With Chemotherapy Sequential With ATG-010 Monotherapy Maintenance in Peripheral T- and NK/T-cell Lymphoma ICE [ifosfamide+carboplatin+etoposide], GEMOX [gemcitabine+oxaliplatin], Tislelizumab - Peripheral T-cell Lymphoma, NK/T-cell Lymphoma | Phase 1 / Phase 2 | Terminated | Antengene Corporation | 56 | 2020-08-18 | 2026-01-05 |
| A Study of Evaluating the Safety and Efficacy of ATG-010 in Relapsed/Refractory Diffuse Large B-Cell Lymphoma ATG-010 60 mg, orally, twice weekly, each 4 week (28-day) a cycle - Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | Phase 2 | Completed | Antengene Corporation | 60 | 2020-04-09 | 2025-02-07 |
| A Study of Evaluating the Safety and Efficacy of ATG-010 in Relapsed Refractory Multiple Myeloma ATG-010 - Relapse/Refractory Multiple Myeloma | Phase 2 | Completed | Antengene Corporation | 82 | 2019-09-02 | 2023-06-15 |
Lymphoma, Large B-Cell, Diffuse (3) · Multiple Myeloma (3) · Recurrence (3) · Leukemia, Myeloid, Acute (1) · Lymphoma, Extranodal NK-T-Cell (1) · Lymphoma, Non-Hodgkin (1) · Lymphoma, T-Cell, Peripheral (1) · Pyloric Stenosis, Hypertrophic (1)
selinexor (8) · Rituximab (4) · Cyclophosphamide (2) · Doxorubicin (2) · Lenalidomide (2) · Prednisone (2) · Vincristine (2) · Bortezomib (1) · Cytarabine (1) · Daunorubicin (1) · Dexamethasone (1) · Exportin 1 Protein (1) · Granulocyte Colony-Stimulating Factor (1) · Homoharringtonine (1) · Ice (1)
China (11)
Bingshan Liu, MD (1) · Jin Lu, PhD (1) · Tao Wang (1) · Tong Chen, Ph.D (1) · Yang Yu (1) · Yang Yu, MD (1) · Ying Jiao, MD (1) · Zhiming Li, Ph.D (1) · Zhongjun Xia, Ph.D (1)